Can gallium-68 compounds partly replace (18)F-FDG in PET molecular imaging?

Area of Science:

• Radiochemistry and Nuclear Medicine
• Molecular Imaging
• Oncology

Background:

• Development of Gallium-68 (68Ga)-DOTA compounds leverages 68Ga's chemistry and the pharmacokinetic compatibility with peptides and chelators like DOTA.
• The availability of 68Ga from a Germanium-68/Gallium-68 (68Ge/68Ga) generator provides a practical alternative to cyclotrons for nuclear medicine departments.

Discussion:

• Clinical applications of 68Ga-peptides include imaging neuroendocrine tumors (carcinoid, pheochromocytoma, paraganglioma) and other conditions.
• Ongoing research explores 68Ga-DOTA conjugates for melanoma, bombesin receptor-positive tumors, tumor hypoxia, and inflammatory reactions.
• The ability to use beta-emitting isotopes labeled to the same peptides offers a pathway for targeted radionuclide therapy following diagnostic imaging.

Key Insights:

• 68Ga-DOTA peptides are effective diagnostic tools for various cancers and inflammatory processes.
• The 68Ge/68Ga generator system enhances accessibility and utility of 68Ga-based radiotracers.
• Dual-modality imaging and therapy approaches are facilitated by the development of these peptide conjugates.

Outlook:

• Further clinical validation and expansion of 68Ga-peptide applications are anticipated.
• Integration into routine clinical practice for tumor and inflammation management is expected.
• Advancements in peptide design and chelator chemistry will likely yield novel 68Ga-based imaging agents.